References: 1. Yen J, Chen S, Jenkins C, et al. BRCA1 promoter methylation in sporadic breast cancer patients detected by liquid biopsy. Poster presented at: American Association for Cancer Research Annual Meeting. April 14-19, 2023; Orlando, FL. Accessed April 12, 2023. 2. Kondrashova O, Topp M, Nesic K, et al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun. 2018;9(1):3970. doi:10.1038/s41467-018-05564-z 3. Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000;92(7):564-569. doi:10.1093/jnci/92.7.564 4. Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in a population-based clinical study. Nat Med. 2019;25(10):1526-1533. 5. Staaf J, Glodzik D, Bosch A, et al. Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. Nat Med. 2019;25(10):1526-1533. doi:10.1038/s41591-019-0582-4 6. Elazezy M, Prieske K, Kluwe L, et al. BRCA promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer. Mol Oncol. 2021;15(12):3615-3625. doi:10.1002/1878-0261.13108
BRCA1 promoter methylation and pathogenic genomic alterations in homologous recombination and repair (HRR) genes are mutually exclusive in cancer patients.1,3-5
Predict clinical response to DNA-damaging chemotherapy with blood-based BRCA1 promoter methylation.⁶
Predict Clinical Response
Promoter methylation biomarkers can expand patient reach or predict response.1,2
Home Guardant Infinity™ for HCPs Treatment Selection Monitoring and MRD Assessment Guardant Infinity™ for BioPharma